2006
A phase I open-label, dose escalation study to determine the maximum tolerated dose and to evaluate the safety profile of lenalidomide with every three week docetaxel in subjects with androgen independent prostate cancer
Moss R, Shelton G, Melia J, Mohile S, Petrylak D. A phase I open-label, dose escalation study to determine the maximum tolerated dose and to evaluate the safety profile of lenalidomide with every three week docetaxel in subjects with androgen independent prostate cancer. Journal Of Clinical Oncology 2006, 24: 14618-14618. DOI: 10.1200/jco.2006.24.18_suppl.14618.Peer-Reviewed Original ResearchAndrogen-independent prostate cancerIndependent prostate cancerMeasurable diseaseProstate cancerSerum prostate-specific antigen levelProstate-specific antigen levelDose escalation schedulePrior chemotherapy regimensEvidence of progressionFurther dose escalationPhase I trialSpecific antigen levelsEfficacy of docetaxelDerivative of thalidomideAntiandrogen withdrawalL1 patientsPalliative RTPo bidStable diseaseChemotherapy regimensMedian PSARECIST criteriaEscalation studySerum PSABone metastases
2002
Chemotherapy for the Treatment of Hormone-Refractory Prostate Cancer
Petrylak D. Chemotherapy for the Treatment of Hormone-Refractory Prostate Cancer. European Urology Open Science 2002, 1: 15-23. DOI: 10.1016/s1569-9056(02)00005-2.Peer-Reviewed Original ResearchHormone-refractory prostate cancerBone painProstate cancerSerum prostate-specific antigen levelProstate-specific antigen levelPhase II trialPhase III trialsSoft tissue metastasesAndrogen ablation therapyEffective palliative therapyAdvanced prostate cancerCombination of mitoxantroneMetastatic prostate cancerTreatment of menHormonal therapyII trialIII trialsOverall survivalPalliative therapyPSA levelsTissue metastasesAntigen levelsTreatment optionsClinical trialsAblation therapy
1999
Which patients with newly diagnosed prostate cancer need a computed tomography scan of the abdomen and pelvis? An analysis based on 588 patients
Lee N, Newhouse J, Olsson C, Benson M, Petrylak D, Schiff P, Bagiella E, Malyszko B, Ennis R. Which patients with newly diagnosed prostate cancer need a computed tomography scan of the abdomen and pelvis? An analysis based on 588 patients. Urology 1999, 54: 490-494. PMID: 10475360, DOI: 10.1016/s0090-4295(99)00150-8.Peer-Reviewed Original ResearchConceptsPositive CT scanGleason scoreComputed tomography scanCT scanClinical stageProstate cancerIndependent predictorsTomography scanSerum prostate-specific antigen levelProstate-specific antigen levelClinical stage T2bLow-risk patientsBiopsy Gleason scoreGleason score 8Negative CT scanAbdominopelvic CT scansGleason score 2Low-risk groupSignificant independent predictorsProstate cancer biopsiesStage T2bPathologic reviewStaging evaluationPositive CTAntigen levels